阿那莫林治疗恶病质的效果怎么样

Anamorelin has a good effect in treating cachexia. It can effectively prevent and reduce the symptoms of patients with cachexia, including reduced red blood cells, weight loss, loss of appetite and other symptoms. It can significantly increase the patient's total weight and lean body mass, and the patient's quality of life can also be relieved and improved accordingly. Anamorelin can be used to treat cancer cachexia (CC) in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors.

Effect of Anamorelin in Treating Cachexia

Background: Cancer anorexia-gout syndrome is associated with increased morbidity and mortality. It is an oral gastrin receptor agonist with appetite-enhancing and anabolic activities. The trial evaluated the effects of anamorelin on body composition, strength, quality of life, biochemistry and safety in patients with cancer anorexia-headache.

research methods

Data were pooled a priori from two completed phase 2, multicenter, placebo-controlled, double-blind trials (NCT00219817 and NCT00267358) in patients with advanced or incurable cancer who had lost 5% or more of their body weight. Patients were stratified by severity of weight loss (5-15%, >15%) and randomized by a computer-generated random assignment table (1:1) to anamorelin 50 mg or placebo once daily for 12 weeks.

The primary study outcome was lean body mass assessed by dual-energy X-ray absorptiometry during 12 weeks of treatment in eligible patients who took at least one dose of study drug and underwent a post-treatment efficacy assessment. Safety assessments were conducted on all patients who took study medication at least once.

Research results

The trial enrolled 44 patients in the anamorelin group and 38 patients in the placebo group. Seventy-four patients were eligible for efficacy analysis. Over 12 weeks, the mean least squares lean body mass increased by 1.89 kg (95% CI 0.84 to 2.95) in the 38 patients in the anamorelin group and decreased by -0.20 kg (-1.23 to 0.83) in the 36 patients in the placebo group (difference 2.09 kg [0.94-3.25]; p=0.0006).

Test safety

Adverse reactions occurred in 42 of 44 patients (95%) who received anamorelin and in 33 of 38 (87%) who received placebo. The most common grade 3-4 adverse events (treatment-related or unrelated) in the anamorelin group were fatigue, asthma, atrial fibrillation, and dyspnea (two [5%] each); in the placebo group, they were pneumonia (three [8%]) and anemia, thrombocytopenia, abdominal pain, anxiety, and dyspnea (two [5%] each).

Test conclusion

Treatment with anamorelin for 12 weeks resulted in a favorable clinical response in patients with cancer anorexia-gout syndrome. These findings support further research in this setting.

Anamorelin drug purchase channels

As of October 10, 2023, anamulin has not been launched in mainland China, and it is not available in hospital pharmacies in mainland China. It is currently known that Anamorelin has been launched in Japan in January 2021. Patients in need can go to Japan to buy it, or they can also obtain it through domestic professional overseas medical service organizations (such as Medical Companion Travel). The drug can be mailed to home, which is convenient and can reduce a lot of financial burden. However, it is restricted by many factors and is not fixed. It is recommended to consult the customer service staff for the specific cost and acquisition process. Obtaining the drug is guaranteed.

Recommended related articles:

References

Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomized, placebo-controlled, double-blind trials. Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16. PMID: 25524795.